1.Yttrium-90 selective internal radiotherapy in conversion treatment of unresectable hepatocellular carcinoma:research progress
Man ZHAO ; Qianwen NI ; Xianjie PIAO ; Xiaoqin WU ; Rui ZHOU ; Kaiting ZHANG ; Zhenguang WANG ; Minghao ZOU ; Wenxuan ZHOU ; Fuchen LIU ; Hui LIU
Academic Journal of Naval Medical University 2025;46(2):189-197
Yttrium-90(90Y)selective internal radiation therapy(SIRT)is an emerging modality for the treatment of hepatocellular carcinoma(HCC),leveraging the nuclide 90Y to deliver targeted radiation therapy.90Y has a long half-life and can be used to selectively ablate tumor cells by high-energy beta rays.It has high biological effectiveness and robust local control capabilities.In recent years,with the continuous advancement of basic and clinical research,the application of 90Y-SIRT in the conversion treatment of unresectable HCC(uHCC)has made significant progress.However,challenges remain in the clinical application of 90Y-SIRT,including how to improve the efficacy of conversion therapy and how to optimize therapy regimens.This review aims to summarize the research progress of90Y-SIRT in the conversion therapy of uHCC.
Result Analysis
Print
Save
E-mail